KIRKLAND, Wash., Nov. 16 /PRNewswire-FirstCall/ -- CellCyte Genetics Corporation (the “Company”) has appointed Tony Colasin as its Director of Business Development and will head CellCyte’s aggressive acquisition and technology licensing efforts.
Tony Colasin was former Sr. Director of Business Development for ICOS Corporation. From January 2001 to January 2007, he directed that company’s business development during several major product introductions. Mr. Colasin managed M&A investment banking engagements, establishing a screening/evaluation process. He led the development and implementation of ICOS’ product licensing review process and standardized valuation techniques (NPV and option valuation), which increased the number of opportunities assessed annually and improved overall capacity for revenue.
Notably, Tony Colasin was responsible for building a urology franchise to leverage the Cialis(R) brand, a treatment for erectile dysfunction successfully launched against Viagra(R). Mr. Colasin led a team that created an integrated business development strategy for the company’s urology franchise and was a member of the Cialis(R) pre-commercialization team created to develop ICOS sales force’s strategy/configuration and pre-launch activities to establish brand character.
While at ICOS Corporation, he also secured a co-promotion agreement of Androgel: successfully led the cross-functional effort to identify products complementary to Cialis(R) and negotiated and executed a multi-million dollar co-promotion agreement for the ICOS sales force. He is also attributed with negotiating rights to a drug used to treat chronic painful bladder syndrome valued at over $25 million, and establishing a $68 million+ strategic alliance and cross-license agreement with a large, potentially competitive biotechnology company.
Prior to ICOS Corporation, Mr. Colasin was Sr. Finance Manager, Corporate Finance, for Amgen, Inc. from November 1998 to December 2000. He was a member of Amgen’s cross-functional team responsible for the evaluation of drug candidates and management of marketed products for the company’s Oncology Franchise. He developed a strong team and led commercial evaluation of oncology-related licensing efforts; he was the finance representative responsible for managing research, a third-party international partnership, and he supported M&A efforts including evaluation of acquisition targets, identifying comparables, determining optimal financing strategy, and supporting SEC filing efforts.
His position as Sr. Finance Manager followed Mr. Colasin’s earlier contributions to Amgen as Marketing Manager, from July 1997 to October 1998, and Financial Analyst for the $1 billion+ drug EPOGEN(R), from February 1996 to June 1997. In his early roles with the company, he played a vital part in analyzing forecasts, financial models and sales trends critical to products and markets that the company was pursuing.
Mr. Colasin’s initial analyst career was as Sr. Analyst for Putnam, Hayes & Bartlett, Inc., an economic and management consulting firm. With the firm, he diagnosed problems, created analytical frameworks, conducted analyses, developed conclusions, and presented recommendations to senior client management. He also provided analytical support to clients involved in a billion dollar+ licensing agreement dispute, including issues related to reimbursement policies, market penetration and product distribution.
Tony Colasin graduated from University of Southern California with a B.S., Business Administration and received his M.B.A, Finance in International Business Emphasis, in June 2000 from the Anderson School at UCLA.
About CellCyte Genetics
CellCyte Genetics, a Washington State company, is an emerging biotechnology company engaged in the principle business of the discovery, development and commercialization of breakthrough stem cell enabling therapeutic products.
www.cellcyte.com
Safe Harbor Statement
THIS NEWS RELEASE CONTAINS “FORWARD-LOOKING STATEMENTS”, AS THAT TERM IS DEFINED IN SECTION 27A OF THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, AND SECTION 21E OF THE UNITED STATES SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. STATEMENTS IN THIS NEWS RELEASE, WHICH ARE NOT PURELY HISTORICAL, ARE FORWARD-LOOKING STATEMENTS AND INCLUDE ANY STATEMENTS REGARDING BELIEFS, PLANS, EXPECTATIONS OR INTENTIONS REGARDING THE FUTURE. EXCEPT FOR THE HISTORICAL INFORMATION PRESENTED HEREIN, MATTERS DISCUSSED IN THIS NEWS RELEASE CONTAIN FORWARD-LOOKING STATEMENTS THAT ARE SUBJECT TO CERTAIN RISKS AND UNCERTAINTIES THAT COULD CAUSE ACTUAL RESULTS TO DIFFER MATERIALLY FROM ANY FUTURE RESULTS, PERFORMANCE OR ACHIEVEMENTS EXPRESSED OR IMPLIED BY SUCH STATEMENTS. STATEMENTS THAT ARE NOT HISTORICAL FACTS, INCLUDING STATEMENTS THAT ARE PRECEDED BY, FOLLOWED BY, OR THAT INCLUDE SUCH WORDS AS “ESTIMATE,” “ANTICIPATE,” “BELIEVE,” “PLAN” OR “EXPECT” OR SIMILAR STATEMENTS ARE FORWARD- LOOKING STATEMENTS. RISKS AND UNCERTAINTIES FOR THE COMPANY INCLUDE, BUT ARE NOT LIMITED TO, THE RISKS ASSOCIATED WITH THE CLOSING OF THE CLOSING OF THE SHARE EXCHANGE AGREEMENT AND THE DEVELOPMENT AND FUNDING OF THE COMPANY CONSEQUENT THEREON, AS WELL AS THE RISKS SHOWN IN THE COMPANY’S MOST RECENT ANNUAL REPORT ON FORM 10-KSB AND ON FORM 10-QSB AND FROM TIME-TO-TIME IN OTHER PUBLICLY AVAILABLE INFORMATION REGARDING THE COMPANY. OTHER RISKS INCLUDE RISKS ASSOCIATED WITH THE REGULATORY APPROVAL PROCESS, COMPETITIVE COMPANIES, FUTURE CAPITAL REQUIREMENTS AND THE COMPANY’S ABILITY AND LEVEL OF SUPPORT FOR ITS RESEARCH AND DEVELOPMENT ACTIVITIES. THERE CAN BE NO ASSURANCE THAT THE COMPANY’S DEVELOPMENT EFFORTS WILL SUCCEED AND THE COMPANY WILL ULTIMATELY ACHIEVE COMMERCIAL SUCCESS.
THESE FORWARD-LOOKING STATEMENTS ARE MADE AS OF THE DATE OF THIS NEWS RELEASE, AND THE COMPANY ASSUMES NO OBLIGATION TO UPDATE THE FORWARD-LOOKING STATEMENTS, OR TO UPDATE THE REASONS WHY ACTUAL RESULTS COULD DIFFER FROM THOSE PROJECTED IN THE FORWARD-LOOKING STATEMENTS. ALTHOUGH THE COMPANY BELIEVES THAT THE BELIEFS, PLANS, EXPECTATIONS AND INTENTIONS CONTAINED IN THIS NEWS RELEASE ARE REASONABLE, THERE CAN BE NO ASSURANCE THOSE BELIEFS, PLANS, EXPECTATIONS OR INTENTIONS WILL PROVE TO BE ACCURATE. INVESTORS SHOULD CONSIDER ALL OF THE INFORMATION SET FORTH HEREIN AND SHOULD ALSO REFER TO THE RISK FACTORS DISCLOSED IN THE COMPANY’S PERIODIC REPORTS FILED FROM TIME-TO- TIME WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION. THIS NEWS RELEASE HAS BEEN PREPARED BY MANAGEMENT OF THE COMPANY WHO TAKE FULL RESPONSIBILITY FOR ITS CONTENTS. EACH OF THE NASD, THE SEC AND THE OTCBB NEITHER APPROVES NOR DISAPPROVES OF THE CONTENTS OF THIS NEWS RELEASE. THIS NEWS RELEASE SHALL NOT CONSTITUTE AN OFFER TO SELL OR THE SOLICITATION OF AN OFFER TO BUY NOR SHALL THERE BE ANY SALE OF THESE SECURITIES IN ANY JURISDICTION IN WHICH SUCH OFFER, SOLICITATION OR SALE WOULD BE UNLAWFUL PRIOR TO REGISTRATION OR QUALIFICATION UNDER THE SECURITIES LAWS OF ANY SUCH JURISDICTION.
CONTACT: CellCyte Genetics Corporation, North America, Investor Relations,
1-877-688-5050, or Europe, Investor Relations, +49-69-7593-8451
Web site: http://www.cellcyte.com/
